You are here

Our science / Clinical Trials / Find a Trial / NCT01251835

Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan

Back to Search Print Save as PDF Bookmark Trial

NCT01251835

Last updated on February 17, 2020
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pulmonary Arterial Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
21-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy male subjects and/or women of non-child bearing potential.

- Subjects between the ages of 21 and 55 years, inclusive.

- Signed informed consent.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease.

- Has hepatic dysfunction.

- Has history of excessive alcohol and tobacco use.

NCT01251835
Pfizer
Withdrawn
Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Pulmonary Arterial Hypertension
Effects of Oral Sildenafil on Mortality in Adults With PAH
NCT02060487
All Genders
18+
Years
Multiple Sites
Pulmonary Arterial Hypertension
Revavtio Special Investigation for Long-term Use in Pediatric Patients
NCT03364244
All Genders
0+
Years
Tokyo,
Descriptive Information
Brief Title  ICMJE Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan
Official Title  ICMJE A Phase 1, Open Label, Fixed Sequence Design, Multiple Dose Study To Assess The Effect Of Rifampin On The Pharmacokinetics Of Sitaxsentan In Healthy Subjects
Brief Summary This study will assess how rifampin will affect the blood levels of sitaxsentan. Safety of sitaxsentan given alone and with rifampin will also be assessed.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Condition  ICMJE Pulmonary Arterial Hypertension
Intervention  ICMJE
  • Drug: Sitaxsentan alone
    Days 1-5: Sitaxsentan tablet, 100 mg, q24 h (once a day)
  • Drug: Sitaxsentan
    Days 6-12: Sitaxsentan tablet, 100 mg, q24h (once a day)
  • Drug: Rifampin
    Days 6-12: Rifampin capsule, 600 mg, q24h (once a day)
Study Arms  ICMJE
  • Active Comparator: Sitaxsentan
    Intervention: Drug: Sitaxsentan alone
  • Experimental: Sitaxsentan plus Rifampin
    Interventions:
    • Drug: Sitaxsentan
    • Drug: Rifampin
Publications * Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: March 4, 2015) 		0
Original Estimated Enrollment  ICMJE
 (submitted: December 1, 2010) 		16
Estimated Study Completion Date  ICMJE January 2011
Estimated Primary Completion Date January 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy male subjects and/or women of non-child bearing potential.
  • Subjects between the ages of 21 and 55 years, inclusive.
  • Signed informed consent.

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
  • Has hepatic dysfunction.
  • Has history of excessive alcohol and tobacco use.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 21 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01251835
Other Study ID Numbers  ICMJE B1321060
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date January 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now